October 21, 2013 | Ariad Pharmaceuticals abruptly terminated a clinical trial for a leukemia drug on Friday, after early trial data from 150 sites suggested safety issues such as blood clots, strokes, and heart attacks. Ariad stock has fallen 84.4% since Friday. However, a spokeswoman for the Leukemia and Lymphoma Society pointed out that the trial did reveal important information. "This is the clinical trial process at work," she said. Boston Globe